Rondonotti Emanuele, Zolk Oliver, Amato Arnaldo, Paggi Silvia, Baccarin Alessandra, Spinzi Giancarlo, Radaelli Franco
Gastroenterology Unit, Ospedale Valduce, Como, Italy.
Institute of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Ulm, Germany.
Gastrointest Endosc. 2014 Dec;80(6):1103-12.e2. doi: 10.1016/j.gie.2014.05.319. Epub 2014 Jul 19.
Hyoscine-N-butylbromide (HBB) can induce flattening of colon folds through inhibition of smooth muscle activity, which improves mucosal visualization. Whether this affects polyp detection is controversial.
To evaluate whether HBB, administered during colonoscopy, improves polyp and adenoma detection.
We performed a comprehensive search in MEDLINE and EMBASE databases to identify randomized, placebo-controlled trials (RCTs) in which HBB was administered during colonoscopy and which also reported the detection rate for polyps and/or adenomas (PDR and/or ADR, respectively).
Meta-analysis of 5 RCTs.
A total of 1998 patients (1006 receiving HBB) were included in the study.
Intravenous administration of 20 mg (2 mL) HBB or 2 mL saline solution at the time of cecal intubation.
The PDR was the primary outcome variable. Secondary outcomes included the ADR, the advanced adenoma detection rate (adv-ADR), and the mean number of polyps and adenomas per patient (PPP and APP, respectively).
The PDR, ADR, and adv-ADR did not differ significantly between the 2 groups. The odds ratios (95% confidence interval [CI]) for PDR, ADR, and adv-ADR were 1.09, 95% CI, 0.91-1.31; 1.13, 95% CI, 0.92-1.38; and 0.9, 95% CI, 0.63-1.30, respectively. In addition, no significant differences were observed in PPP and APP between the 2 groups.
Small number of studies included. Limited data about secondary outcomes and safety.
Our meta-analysis does not provide evidence that routine HBB administration at cecal intubation improves PDR or ADR. More studies are needed for final conclusions, particularly on HBB's effect on PPP and APP.
丁溴东莨菪碱(HBB)可通过抑制平滑肌活动使结肠皱襞变平,从而改善黏膜可视化。这是否会影响息肉检测存在争议。
评估结肠镜检查期间给予HBB是否能改善息肉和腺瘤的检测。
我们在MEDLINE和EMBASE数据库中进行了全面检索,以识别在结肠镜检查期间给予HBB且报告了息肉和/或腺瘤检测率(分别为PDR和/或ADR)的随机、安慰剂对照试验(RCT)。
对5项RCT进行荟萃分析。
共有1998例患者(1006例接受HBB)纳入研究。
在盲肠插管时静脉注射20mg(2mL)HBB或2mL生理盐水溶液。
PDR是主要结局变量。次要结局包括ADR、高级腺瘤检测率(adv - ADR)以及每位患者的息肉和腺瘤平均数量(分别为PPP和APP)。
两组之间的PDR、ADR和adv - ADR无显著差异。PDR、ADR和adv - ADR的优势比(95%置信区间[CI])分别为1.09,95%CI:0.91 - 1.31;1.13,95%CI:0.92 - 1.38;和0.9,95%CI:0.63 - 1.30。此外,两组之间的PPP和APP也未观察到显著差异。
纳入研究数量少。关于次要结局和安全性的数据有限。
我们的荟萃分析未提供证据表明在盲肠插管时常规给予HBB可改善PDR或ADR。需要更多研究得出最终结论,特别是关于HBB对PPP和APP的影响。